Someone warned you on the 12th of Nov..Now they've loaded all you retailers up in this with the constant
drumming of buy, buy, buy..now we find that the hedgies are selling...classic....for the small players.
Buy at the top,,,and ride it down...
Actually,,,the PE is 31 times next years earnings...This won't continue to grow at this
pace. Volume has been slowly going down. This is the ultimate bubble stock. I expect
a correction of at least 25% soon...
Windy..you are a well regarded long...being such, you have to know Fud is Bi-polar...Some days
you get the good fud,,,other days,,usually late in the day,,,you get the evil...fud,,,
Biogen Idec's (Nasdaq: BIIB) potential treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, has failed in a late-stage clinical trial, disappointing the company, patients and doctors. In a best-case scenario, that Phase 3 trial would have formed the basis of an application for U.S. Food and Drug Administration (FDA) approval.
Weston, Mass.-based Biogen’s stock slid more than 3 percent Thursday morning, to $144.79, from a previous close of $150, after the company announced the news.
The failure of the 900-patient Empower trial was so complete that the company will abandon development of the drug candidate, called dexpramipexole, or Dex.